Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing.
Immunotherapy in Stage III NSCLC: The Practice-Changing Results of the PACIFIC Trial Usher in a New Standard (BMIC-006)
